AGM/EGMJun 26, 2026, 08:41 AM
BridgeBio Pharma Shareholders Elect Directors, Approve Stock Plan
AI Summary
BridgeBio Pharma, Inc. announced the results of its 2026 Annual Meeting of Stockholders. Shareholders elected three Class I directors, approved executive compensation on an advisory basis, and ratified Deloitte & Touche LLP as the independent auditor. Additionally, the amendment and restatement of the 2021 Stock Option and Incentive Plan was approved, increasing shares reserved for issuance by 2,000,000. Dr. Randal W. Scott also resigned from the Board of Directors, effective June 22, 2026, upon completion of his term.
Key Highlights
- Dr. Randal W. Scott resigned from BridgeBio Pharma's Board of Directors.
- Shareholders elected three Class I directors: James C. Momtazee, Frank P. McCormick, and Hannah A. Valantine.
- Advisory vote on executive compensation was approved with 152,949,577 votes for.
- Shareholders approved an annual frequency for future advisory votes on executive compensation.
- Deloitte & Touche LLP was ratified as the independent auditor for fiscal year 2026.
- The 2021 Stock Option and Incentive Plan was amended to increase shares reserved by 2,000,000.
- 175,706,357 shares were present or represented at the Annual Meeting.
Price Impact
More from BBIO